Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Voyager Therapeutics Inc

VYGR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$3.27

▲ +1.55%

Market Cap $201.49M · Vol 119.08K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$201.49M

Micro Cap

Div Yield

N/A

EPS Growth

+18.50%

YoY

RSI (14)

60.34

Momentum

Beta

1.31

vs Market

52W High

$5.55

41.08% below

52W Low

$2.94

11.41% above

Volume

119.08K

Avg 205.80K

P/B

1.18

Price-to-book

ROE

-48.29%

Return on equity

Free Float

84.92%

Public shares

Shariah Compliance8 STANDARDS

✗ Voyager Therapeutics Inc (VYGR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VYGR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+3.48%

-22.88%

-3.54%

YTD

-16.79%

-12.10%

-65.58%

+10.47%

Financials & Valuation

TTM · Annual

Total Revenue	$40.37M
Net Income	$-119,721,000.00
Revenue Growth (YoY)	-39.13%
Gross Margin	100.00%
Operating Margin	-326.56%
Net Profit Margin	-296.53%
ROE	-48.29%
ROA · ROIC	-37.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.71
P/B	1.18
P/FCF	N/A
EPS Growth	+18.50%
Outstanding Shares	61.62M

Technical Indicators

50-Day SMA	$3.35
200-Day SMA	$3.84
RSI (14)	60.34
Beta	1.31
52-Week High	$5.55
52-Week Low	$2.94

Volume Today	119.08K
Avg Daily Volume (30D)	205.80K
Relative Volume	0.58x
Volatility (10D)	33.86
Volatility (30D)	48.04
Free Float	84.92%

Analyst Consensus

STRONG BUY

Current Price $3.27

Mean Target $14.89

52W Low$2.94 52W High$5.55

Current

Target

$2.94 $5.55

Current Analyst target

+355.32% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG005ZSY242

ISINUS92915B1061

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.